Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through…
14 analysts rate BLCO Hold on consensus.
Consensus price target: $19.39 (+10.99% upside from $17.47)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Ross Thomas W. Sr. director | Mar 3, 2026 | Purchase | 4,500 | $79.56K |
| Alfonso Eduardo director | Mar 2, 2026 | Purchase | 4,300 | $76.97K |
| VON ESCHENBACH ANDREW C. director | Feb 27, 2026 | Purchase | 4,364 | $79.88K |
| COLLIS STEVEN H director | Feb 23, 2026 | Purchase | 15,000 | $267.15K |
| ROBERTSON RUSSEL C director | Feb 20, 2026 | Purchase | 4,400 | $78.76K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $5.1B | +6.47% | $-360M |
| 2024 | $4.79B | +15.56% | $-317M |
| 2023 | $4.15B | +10.03% | $-260M |
Stock data for BLCO: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics